× ×ª×× × ×ª×¨×פ×
××רש×
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
L01XL
Antineoplastic cell and gene therapy
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
- ANTI-CD19 CAR T CELLS 0.4-2x10^8 CELLS/ BAG âL01XL06
|
| צ×רת ×ת×
|
ת××-×ר××× - I.V
|
| צ×רת ××× ××
|
DISPERSION FOR INFUSION
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Acute Lymphoblastic Leukaemia Tecartus is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).Mantle Cell Lymphoma Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor unless ineligible to BTK inhibitor â¢Limitation of Use : TECARTUS is not indicated for the treatment of patients with active central nervous system lymphoma
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 03/02/2022
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×. ×תר××¤× ×ª×× ×ª× ×××פ×× ××××פ××× ×ס×× Mantle cell, ×××רת ×× ×¨×¤×¨×§××ר×ת, ××¤× Cheson criteria, ×××ר ×©× × ×§××× ××פ×× ×¡×ס××××× ×××¢××, ×××× ××¢×× BTK. ×. ××ª× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×××× ×§×××××× ×× ××××× ××××××××××.
|
03/02/2022 |
××× ×§×××××× |
|
Mantle cell lymphoma |
|
| ××ק××× ×ס×× B-cell Acute lymphoblastic leukemia ×××רת ×× ×¨×¤×¨×§××ר×ת, ××××× ×××ר. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×××ת ×××× â Brexucabtagene autoleucel, Tisagenlecleucel.
|
01/02/2023 |
××× ×§×××××× |
|
ALL, Acute lymphoblastic leukemia |
|
| ×××פ××× ×ס×× Mantle cell, ×××רת ×× ×¨×¤×¨×§××ר×ת, ××¤× Cheson criteria, ×××ר ×©× × ×§××× ××פ×× ×¡×ס××××× ×××¢××, ×××× ××¢×× BTK. ××××× ××××ª× ×××× ××××× ×××× ×××ת ××תר×פ×ת â Brexucabtagene autoleucel, Pirtobrutinib.
|
19/02/2025 |
××××××××× |
|
MCL, Mantle cell lymphoma |
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- ×××פ××× ×ס×× Mantle cell, ×××רת ×× ×¨×¤×¨×§××ר×ת, ××¤× Cheson criteria, ×××ר ×©× × ×§××× ××פ×× ×¡×ס××××× ×××¢××, ×××× ××¢×× BTK.
××××× ××××ª× ×××× ××××× ×××× ×××ת ××תר×פ×ת - Brexucabtagene autoleucel, Pirtobrutinib
- ××ק××× ×ס×× B-cell Acute lymphoblastic leukemia ×××רת ×× ×¨×¤×¨×§××ר×ת, ××××× ×××ר.
××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×××ת ×××× - Brexucabtagene autoleucel, Tisagenlecleucel
- ××ª× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×××× ×§×××××× ×× ××××× ××××××××××
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
| ××פ×ש ×××ר××
|
×××ר×× ×-PubMed
|
| ××××¢ ×רשת
|
RxList WebMD Drugs.com
|
| ×©× ×צר×
|
KITE PHARMA, INC., USA
|
| ×©× ××¢× ×ר×ש××
|
GILEAD SCIENCES ISRAEL LTD
|
| ר×ש×××
|
ת×ר×× ××ש×: 8/2020. ר×ש××× ×ת×ר××:
|
| ת×ר×× ×¢×××× ××ר××
|
25/01/2025
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 25/01/2025
KITE
×ק×ר××ס - Tecartus
true
השינוי האחרון נעשה בֹ־25 בינואר 2025 ב־16:16
